| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679966 | Alzheimer's & Dementia | 2018 | 13 Pages |
Abstract
These findings may provide support for expanding preclinical Tg mouse studies in AD with a TBI weight drop model, insights into the progression of pathological targets, their relations to apoptosis, and timing of interventions against these targets and apoptosis. Such studies may demonstrate the potential for drugs to effectively and safely inhibit preprogrammed cell death as a new drug development strategy for use in the fight to defeat AD.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Robert E. Becker, Dimitrios Kapogiannis, Nigel H. Greig,
